Clinical trials
Phase 3 Neoplasms trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
129 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 7 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 8 |
| 2011 | 6 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 7 |
| 2016 | 6 |
| 2017 | 5 |
| 2018 | 8 |
| 2019 | 11 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 70 |
| Active, not recruiting | 23 |
| Terminated | 22 |
| Recruiting | 10 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 14 |
| AbbVie | 10 |
| Amgen | 8 |
| AstraZeneca | 7 |
| Bayer | 6 |
| Hoffmann-La Roche | 5 |
| Sanofi | 4 |
| Daiichi Sankyo | 3 |
| Genmab | 3 |
| GlaxoSmithKline | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 129 |
| Neoplasm Metastasis | 20 |
| Neoplasms by Site | 16 |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Breast Neoplasms | 13 |
| Carcinoma | 10 |
| Recurrence | 10 |
| Colorectal Neoplasms | 9 |
| Adenocarcinoma | 8 |
| Lung Neoplasms | 8 |
Trials
Showing 1 to 25 of 129. Each trial links to its page on Pharma Observatory.
29 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.